Solventum Corporation (SOLV)
NYSE: SOLV · Real-Time Price · USD
73.38
+1.73 (2.41%)
At close: May 8, 2026, 4:00 PM EDT
71.96
-1.42 (-1.94%)
After-hours: May 8, 2026, 7:54 PM EDT
Solventum Revenue
Solventum had revenue of $2.01B in the quarter ending March 31, 2026, a decrease of -3.04%. This brings the company's revenue in the last twelve months to $8.26B, down -0.55% year-over-year. In the year 2025, Solventum had annual revenue of $8.33B with 0.86% growth.
Revenue (ttm)
$8.26B
Revenue Growth
-0.55%
P/S Ratio
1.54
Revenue / Employee
$401,380
Employees
20,584
Market Cap
12.71B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 8.33B | 71.00M | 0.86% |
| Dec 31, 2024 | 8.25B | 57.00M | 0.70% |
| Dec 31, 2023 | 8.20B | 67.00M | 0.82% |
| Dec 31, 2022 | 8.13B | -41.00M | -0.50% |
| Dec 31, 2021 | 8.17B | 890.00M | 12.22% |
| Dec 31, 2020 | 7.28B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Baxter International | 11.32B |
| Avantor | 6.55B |
| ResMed | 5.54B |
| Bausch + Lomb | 5.10B |
| The Cooper Companies | 4.15B |
| Align Technology | 4.10B |
| AptarGroup | 3.87B |
| West Pharmaceutical Services | 3.22B |
SOLV News
- 1 day ago - Solventum to Participate in the 2026 BofA Securities Health Care Conference - PRNewsWire
- 1 day ago - Solventum price target raised to $93 from $92 at KeyBanc - TheFly
- 1 day ago - Solventum price target lowered to $90 from $105 at Stifel - TheFly
- 1 day ago - Solventum price target lowered to $78 from $82 at UBS - TheFly
- 3 days ago - Solventum forecasts annual profit at higher end on wound care demand - Reuters
- 3 days ago - Solventum Earnings Call Transcript: Q1 2026 - Transcripts
- 3 days ago - Solventum Reports First Quarter 2026 Financial Results - PRNewsWire
- 7 days ago - Peltz's Trian urges Solventum to rightsize costs, divest non-core businesses - Reuters